Skip To Main Content
This website contains promotional content and is intended for Healthcare Professionals in the Republic of Ireland only. Adverse event reporting can be found at the bottom of the page
Campus
Campus
  • Article
  • Source: Campus Sanofi

SPARTA Study

Author : Sanofi
Editorial Team

All relevant safety information about adverse reactions, precautions, and relevant contraindications can be found on the product page HERE.

Sparta Summary

In this clinical summary you discover the real-world evidence of Toujeo® Insulin Glargine 300U/ml in people with T1 diabetes living in the UK. This was conducted in the SPARTA study - a descriptive, retrospective study.

Download

See More From Science

Toujeo

Toujeo® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. 

Patient Materials

Find resources and support for your patients who have been prescribed Toujeo®.  This section will help you to help your patients understand the basis of living and staying well with diabetes and how to have a a positive start and experience with Toujeo®. 

Our Products

Toujeo® Product Page 

Prescribing Information

 

MAT-IE-2300465 (v1.0)
Date of preparation: March 2026

MAT-IE-2300499 (v2.0) Date of Preparation: March 2026